Lumexa Imaging is a freshly listed outpatient imaging platform whose first public year is testing whether an advanced-mix flywheel can outrun leftover sponsor leverage and a new public-company cost layer. The December listing converted a Welsh Carson backed roll-up into a Nasdaq name and used almost all of the offering cash to refinance the term loan stack. That recap is the reason GAAP turned profitable even as Adjusted EBITDA, the cash-earnings proxy management uses to strip interest, taxes, depreciation and selected items, sat essentially flat. The market is no longer paying the offering multiple because mid-single-digit revenue growth and a one-point margin fade do not look like a compounding platform. The debate is whether same-center magnetic resonance and computed tomography volume, new joint ventures, and a second-half cash season are enough to prove the listing was a recapitalization of a durable site-of-care shift rather than the exit of a mature consolidator.
The second-quarter print is the first clean look at the recap working through the income statement. Consolidated revenue reached $264 million. That mid-single-digit gain came almost entirely from magnetic resonance and computed tomography volume rather than from more routine X-ray visits. Same-center advanced volume rose just over five percent, which is the organic read that strips new sites and is the cleanest test of whether referring physicians keep sending higher-reimbursed scans. Net income flipped to a small profit because interest expense roughly halved after the offering proceeds retired the old term loans. Adjusted EBITDA barely moved, and the margin slipped a point as listing costs that did not exist last year landed in the run-rate. The recap repaired the residual claim, but it did not yet repair operating leverage.
The tension is that full-year guidance still points to roughly four percent Adjusted EBITDA growth once about $7 million of new public-company costs sit in the year, versus the seven percent that the same midpoint implies on a like-for-like basis. Flat first-half earnings against a still-levered $825 million term loan leave little room for a reimbursement cut, a radiologist wage spike, or a stalled de novo ramp. Material weaknesses in internal control over financial reporting remain from the annual filing, which is a governance tax a newly public roll-up can ill afford if the equity is asking investors to trust adjusted metrics. The bear case is that this is a sponsor leftover whose growth already decelerated from last year's high-single-digit print and whose cash conversion is seasonal and thin.
The next several prints decide whether the Hospital for Special Surgery joint venture and the first University of Pittsburgh Medical Center site are the start of another partnership wave or isolated logos. FastScan magnetic resonance adoption and a second-half cash season are the operating tests that either restore the compounding story or confirm the listing discount. If same-center advanced growth holds and the de novo class ramps without another margin fade, the listing multiple starts to look like a recap discount rather than a growth disappointment.